The updated COVID-19 vaccine is tailored to the Omicron XBB.1.5 sublineage of SARS-CoV-2 and is recommended for individuals 6 months of age and older
NIH’s candidate is based on the Adenovirus 4 backbone, largely used as a vector candidate in HIV and influenza vaccine clinical trials
Lupin actively contributes to alleviating the burden of COPD for patients across the nation
The product is being launched in August 2023
Take proper precautions and seek timely treatment!
Tiotropium (as bromide monohydrate) 18 micrograms powder for inhalation in capsule
Long COVID is a debilitating chronic condition that has affected over 100 million people globally
The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency (EMA), Swissmedic in Switzerland, and the Therapeutic Goods Administration (TGA) in Australia
Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials
This product will be manufactured at Lupin's Pithampur facility in India
Subscribe To Our Newsletter & Stay Updated
